Medical School, Hunan University of Chinese Medicine, Changsha, China.
Department of Oncology, Hunan Academy of Traditional Chinese Medicine Affiliated Hospital, Changsha, China.
Curr Treat Options Oncol. 2024 Nov;25(11):1374-1389. doi: 10.1007/s11864-024-01256-7. Epub 2024 Oct 22.
Bone metastasis, a frequent and detrimental complication of advanced cancers, often triggers bone deterioration events that severely compromise patient quality of life and prognosis. The past few years have witnessed the emergence and continuous advancements in immunotherapy, ushering in innovative therapeutic prospects for bone metastasis. These advancements include not only the use of immune checkpoint inhibitors (ICIs), both as standalone and combined treatments, but also the investigation of novel targets within immune cells residing in bone metastases. These breakthroughs have instilled fresh optimism for effectively managing patients with bone metastasis. This article endeavors to present an exhaustive review of the recent progress made across a spectrum of immunotherapeutic strategies and targeted therapies specifically designed for individuals battling bone metastasis from malignant tumors. By doing so, it seeks to offer insights that can inform clinical practices and guide further medical research in this domain.
骨转移是晚期癌症常见且有害的并发症,常引发严重影响患者生活质量和预后的骨恶化事件。过去几年见证了免疫疗法的出现和不断发展,为骨转移带来了创新的治疗前景。这些进展不仅包括免疫检查点抑制剂(ICIs)的单独和联合使用,还包括对骨转移部位免疫细胞内的新型靶点的研究。这些突破为有效治疗骨转移患者带来了新的希望。本文旨在全面回顾针对恶性肿瘤骨转移患者的一系列免疫治疗策略和靶向治疗的最新进展,为临床实践提供信息,并指导该领域的进一步医学研究。